Intas Pharmaceuticals Ltd continues to pledge their
commitment to increasing access to high quality medicines by
entering into an exclusive license agreement
AHMEDABAD, India, July 22, 2021 /PRNewswire/ -- Intas
Pharmaceuticals Ltd continues to pledge their commitment to
increasing access to high quality medicines by entering into an
exclusive license agreement with Meiji and Dong-A Socio Holdings (a
parent company of Dong-A ST) to commercialize DMB-3115, a proposed
biosimilar to ustekinumab, a recombinant monoclonal antibody for
the treatment of autoimmune and inflammatory diseases such as
plaque psoriasis, Crohn's disease and ulcerative colitis.
Under the terms of the agreement, Intas have been granted
exclusive license rights to commercialize DMB-3115 worldwide,
excluding Japan, Korea and certain
countries in Asia. Meiji and
Dong-A ST will develop and manufacture DMB-3115 and supply the
product to Intas and its worldwide affiliates.
This is yet another industry first for Intas, one of the leaders
in the development and commercialization of biosimilar products,
who are the first Indian company to launch a biosimilar product in
the EU.
"We are truly excited by this partnership, which brings together
the development expertise of Meiji and Dong-A ST with the
extensive commercial reach of Intas," said Vice Chairman, Mr.
Binish Chudgar. "This agreement
underlines our vision and commitment to increase access to
life-changing medicines that can make a real difference to patient
lives across the world," said Chrys
Kokino, President of Accord BioPharma, Inc., the US
specialty subsidiary of Intas.
About Dong-A ST
Dong-A is one of the leading pharmaceuticals in Korea. Dong-A
has solidified its leading market position on the strength of
in-house developed products such as Suganon tab. Evogliptin, the
DPP-4 inhibitor for type 2 diabetes mellitus, Zydena tab. Udenafil,
the fourth PDE5 inhibitor in the world for erectile dysfunction,
Stillen tab. Eupatilin for herbal treatment of gastritis and
Motilitone tab. Corydaline for functional dyspepsia. Furthermore,
Dong-A offers branded generic drugs (anti-cancer, anti-TB, etc.),
bio-pharmaceutical, IMD, APIs and OTC products ensuring full
compliance with international quality standard. Currently Dong-A
exports its products to more than 50 countries to leading
pharmaceutical companies in Europe, Latin
America and Asia.
For more information, please visit http://en.donga-st.com.
About Meiji
Meiji is a leading pharmaceutical company in Japan in the therapeutic areas of infectious
diseases and central nervous system disorders. Since entering
pharma industry with launch of penicillin in 1946, Meiji has been
accumulating proprietary technologies on R&D and manufacture of
small molecules as well as biotherapeutics and is providing
high-quality pharmaceutical products to customers in Japan and overseas. Meiji continues to
accommodate customer's diverse medical requirements as a "Specialty
and Generic Pharmaceuticals Company".
For more information, please visit
https://www.meiji.com/global/about-us/corporate-profile/meiji-seika-pharma/
About Intas
Intas Pharmaceuticals Ltd. is a leading vertically integrated
pharmaceutical company based in Ahmedabad, India, having end-to-end capabilities of
formulation development, manufacturing and marketing along with
backward integration of APIs. Intas has more than 16,000 employees,
sells products in more than 85 countries and has 14 manufacturing
sites worldwide. The Intas group's revenues amounted to
USD 2.1 bn in FY 2020 and the
compounded annual growth rate of Intas' revenues has exceeded 25%
in the past 10 years.
For more information, please visit www.intaspharma.com